STOREDB:STUDY1082 Liver and Spleen Tumours in Rats After Injection of Th-230 Enriched Thorotrast [DOI:10.20348/STOREDB/1082]
|Liver and Spleen Tumours in Rats After Injection of Th-230 Enriched Thorotrast|
|Published: Open access to everyone|
|BIOLOGICAL SAMPLE AVAILABLE|
|Purpose: To determine the respective roles of the radioactive and chemical component in Thorotrast gel-induced tumours, alpha radioactivity in Thorotrast was enriched about 50 times by addition of Th-230.
Status: 1975-1979, terminated
Treatment: Single i.v. injection with different amounts of variously enriched Thorotrast (see below)
Dosimetry: Activity delivered
Endpoints: Life-span study (spontaneous death) with macroscopic/microscopic pathology
Animal: Female Wistar rats aged 12±2 weeks at injection.
Results: The number of animals that developed liver or spleen tumours increased by a factor of 19 in the highest dose-rate groups compared to controls. There was a linear correlation between dose rate and the number of liver and spleen tumours. An increase of the number of injected Thorotrast particles, providing a constant dose rate, had little influence on tumour incidence. However, at a constant relative dose-rate of ten, a fifty-fold increase in the number of particles (12-600 μl) shortened the minimal tumour latency time by about 250 days. The induced liver tumours showed mostly the same morphology as those observed in Thorotrast patients except for a special type of sarcoma which, so far, has not been seen in man and was interpreted as a Kupffer cell sarcoma. No excess lung tumours due to the exhalation of Rn-220 was observed.
STOREDB:DATASET1122 Link to data and details in ERA [DOI:10.20348/STOREDB/1082/1122]
Created on:2017-05-03 10:45:56 Modified On:2017-05-03 10:45:56
|Link to data and details in ERA|
|LINK TO FILE|